PROMO

Promore Pharma

Market Cap 299.5M

Promore Pharma (Promore, the Company) is a rarity in the Nordic Life Science sector: a biotech company with two first-in-category late-stage clinical programs. The company is an old player in a new uniform, having started as a collection of projects under Karolinska Development’s umbrella but transcended into a separate company and IPO’d in July 2017 on Nasdaq First North. Promore focuses on the development of peptide drugs and have sifted through its collection of programs and chosen PXL01 and LL-37 as their main focus. Both drugs are geared towards underserved markets where good data would make Promore the market leader. PXL01 is set to enter a Phase III program with two separate studies being conducted in EU/India and US/Canada. LL-37 is entering Phase IIb for venous leg ulcers (VLU) and could also be studied in diabetic foot ulcers (DFU). In practice, Promore is a virtual company, outsourcing both production and the clinical development. In order to complete the clinical program Promore has signed partnering deals for the production and clinical development of PXL01 in Europe and India, as well as for the development and commercialization of PXL01 in North America. Promore does not generate any revenues today but future income can materialize in the form of milestone payments and product sales.

+ more
Today
Day High
14.90
14.8
Day Low
14.45
Day Open
14.90
Prev Close
15.90
VWAP
14.8
Volume
5K
Turnover
0.077M
Top Broker
VWAP
15.1
Avg Volume
2K
Avg Turnover
0.027M
Top Brokers
AVA/MLI
VWAP
15.4
Avg Volume
3K
Avg Turnover
0.043M
Top Brokers
AVA/MLI
VWAP
15.3
Avg Volume
2K
Avg Turnover
0.030M
Top Brokers
AVA/MLI
52 week summary
Price Range
9.1
Last
18.8
Beta
N/A
Market Cap
299.5M
Total Return
1.9%
Trailing P/E
-36.1
Div Yield
0.0%
Shares Outstanding
20.2M
Stock Exchange
First North Stockholm
5 day chart Go to advanced chart

Identify and measure trend strength in stocks with our Momentum tool to identify potential entry and exit signals. The tool provides a set of the most simple but powerful indicators that identify whether a stock is under sell or buy pressure.

Relative Price Strength
Change 3 Months 42.7%
Change 12 Months -11.7%
Volume Trend
Average Volume 10 vs 60 Days -15.0%
Price VS
52 Week High -21.3%
50 Day Moving Average 13.2%
200 Day moving Average 31.5%

Add article markers

Compare Promore Pharma to

Prev Close 0 Change 0
High 0 Avg Daily Volume 0
Low 0 Avg Daily Turnover 0
Last updated: 2017-11-23 Source: Redeye
Major Owners Equity Votes
Rosetta 32.6%
32.6%
Mohammed Al Amoudi 32.6%
32.6%
Pharma Research Products Ltd 16.9%
16.9%
Avanza Pension 1.5%
1.5%
Mikael Lönn 1.1%
1.1%
Chalmers Tekniska Högskola 0.6%
0.6%
Philip Diklev 0.5%
0.5%
Arne Andersson 0.5%
0.5%
Victor Victor 0.4%
0.4%
Hans Ostler 0.3%
0.3%
Last updated: 2018-01-17 Source: Redeye/Holdings
Timeframe Transactions Net Shares
Last 12 weeks
0 Purchases
0
0 Sales
0
Last 24 weeks
0 Purchases
0
0 Sales
0
Report Date Name Position Transaction Shares Chg Est Value (SEK)

Insider trades are behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Source: Millistream
  •  
  • Profitability
  • ROE
  • ROCE
  • ROIC
  • EBITDA margin
  • EBIT margin
  • Net margin
  • Per share data (SEK)
  • EPS
  • EPS adj
  • Dividend
  • Net debt
  • Total shares
  • Valuation
  • EV (SEKm)
  • P/E
  • P/E diluted
  • P/Sales
  • EV/Sales
  • EV/EBITDA
  • EV/EBIT
  • P/BV
  • Capital structure
  • Equity ratio
  • Debt/equity ratio
  • Net debt(SEKm)
  • Capital employed(SEKm)
  • Capital turnover rate
  • (SEKm)
  • Net sales
  • Total operating costs
  • EBITDA
  • Depreciation
  • Amortization
  • Impairment charges
  • EBIT
  • Share in profits
  • Net financial items
  • Exchange rate dif.
  • Pre-tax profit
  • Tax
  • Net earnings
  • (SEKm)
  • Assets
  • Current assets
  • Cash in banks
  • Receivables
  • Inventories
  • Other current assets
  • Current assets
  • Fixed assets
  • Tangible assets
  • Associated comp.
  • Investments
  • Goodwill
  • Cap. exp. for dev.
  • O intangible rights
  • O non-current assets
  • Total fixed assets
  • Deferred tax assets
  • Total (assets)
  • Liabilities
  • Current liabilities
  • Short-term debt
  • Accounts payable
  • O current liabilities
  • Current liabilities
  • Long-term debt
  • O long-term liabilities
  • Convertibles
  • Total Liabilities
  • Deferred tax liab
  • Provisions
  • Shareholders' equity
  • Minority interest (BS)
  • Minority & equity
  • Total liab & SE
  • (SEKm)
  • Net sales
  • Total operating costs
  • Depreciations total
  • EBIT
  • Taxes on EBIT
  • NOPLAT
  • Depreciation
  • Gross cash flow
  • Change in WC
  • Gross CAPEX
  • Free cash flow
  • 2015
  •  
  • 0.0%
  • 0.0%
  • 0.0%
  • 0.0%
  • 0.0%
  • 0.0%
  •  
  • 0.00
  • 0.00
  • 0.00
  •  
  • 0.0
  •  
  • 0.0
  • 0.0
  • 0.0
  • 0.0
  • 0.0
  • 0.0
  • 0.0
  • 0.0
  •  
  • 0.0%
  • 0.0%
  • 0
  • 0
  • 0.0
  • 2015
  •  
  •  
  • 0
  • 0
  • 0
  • 0
  • 0
  •  
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  •  
  •  
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2015
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2015 Q1
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2015 Q2
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2015 Q3
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2015 Q4
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2016
  •  
  • 0.0%
  • -186.9%
  • 0.0%
  • -86.8%
  • -104.9%
  • -113.9%
  •  
  • 0.00
  • 0.00
  • 0.00
  •  
  • 0.0
  •  
  • 1.4
  • 0.0
  • 0.0
  • 0.0
  • 0.1
  • -0.2
  • -0.1
  • 0.0
  •  
  • 26.3%
  • 100.0%
  • 1
  • 5
  • 0.8
  • 2016
  •  
  •  
  • 6
  • 0
  • 0
  • 0
  • 7
  •  
  • 0
  • 0
  • 0
  • 0
  • 0
  • 4
  • 2
  • 6
  • 0
  • 13
  •  
  •  
  • 0
  • 2
  • 0
  • 2
  • 8
  • 0
  • 0
  • 10
  • 0
  • 0
  • 3
  • 0
  • 3
  • 13
  • 2016
  • 10
  • -19
  • -2
  • -11
  • 0
  • -11
  • 2
  • -9
  • 1
  • -8
  • -16
  • 2016 Q1
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2016 Q2
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2016 Q3
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2016 Q4
  • 10
  • -19
  • -9
  • -2
  • 0
  • 0
  • -11
  • 0
  • -1
  • 0
  • -11
  • 0
  • -12
  • 2017
  •  
  • -24.8%
  • -24.6%
  • -200.3%
  • -62.3%
  • -62.3%
  • -55.0%
  •  
  • -0.42
  • -0.42
  • 0.00
  •  
  • 20.2
  •  
  • -62.3
  • 0.0
  • 0.0
  • 0.0
  • -4.0
  • 6.4
  • 6.4
  • 0.0
  •  
  • 92.1%
  • 100.0%
  • -62
  • 3
  • 0.2
  • 2017
  •  
  •  
  • 63
  • 2
  • 0
  • 0
  • 65
  •  
  • 0
  • 0
  • 0
  • 0
  • 0
  • 3
  • 3
  • 6
  • 0
  • 71
  •  
  •  
  • 0
  • 3
  • 1
  • 5
  • 1
  • 0
  • 0
  • 6
  • 0
  • 0
  • 66
  • 0
  • 66
  • 71
  • 2017
  • 16
  • -25
  • 0
  • -10
  • 0
  • -10
  • 0
  • -10
  • 1
  • 0
  • -8
  • 2017 Q1
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2017 Q2
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2017 Q3
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2017 Q4
  • 16
  • -25
  • -10
  • 0
  • 0
  • 0
  • -10
  • 0
  • 1
  • 0
  • -9
  • 0
  • -9
  • 2018 E
  • 2018 E
  • 2018 E
  • 2018 E
  • 2019 E
  • 2019 E
  • 2019 E
  • 2019 E
  • 2020 E
  • 2020 E
  • 2020 E
  • 2020 E

Estimated Values are behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Last updated: 2018-02-07 Source: Redeye
Source: Redeye

Presentations, research interviews and videos from our events listed here.

Source: Redeye

When selecting comparable companies, we try to group companies that are in the same or similar sector or subsector. But, more important, have growth, margins and risk characteristics similar to the company being valued.

Community Posts

Be the first to write something about this company in the community.

Create new post